Pliant Therapeutics Capital Expenditures Over Time
| PLRX Stock | USD 13.56 0.47 3.35% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Pliant Therapeutics Performance and Pliant Therapeutics Correlation. Pliant |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pliant Therapeutics. If investors know Pliant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pliant Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.35) | Quarterly Revenue Growth (1.00) | Return On Assets (0.28) | Return On Equity (0.48) |
The market value of Pliant Therapeutics is measured differently than its book value, which is the value of Pliant that is recorded on the company's balance sheet. Investors also form their own opinion of Pliant Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pliant Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pliant Therapeutics' market value can be influenced by many factors that don't directly affect Pliant Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pliant Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pliant Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pliant Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Capital Expenditures Analysis
Compare Pliant Therapeutics and related stocks such as Relay Therapeutics, Stoke Therapeutics, and Black Diamond Therap Capital Expenditures Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RLAY | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 8 M | 1.9 M | 3.5 M | 9.1 M | 4.1 M | 5.2 M |
| STOK | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 113 K | 935 K | 1.6 M | 1.1 M | 1.2 M | 4 M | 1.6 M | 1.7 M |
| BDTX | 77 K | 77 K | 77 K | 77 K | 77 K | 77 K | 77 K | 77 K | 76 K | 21 K | 142 K | 2.7 M | 192 K | 33 K | 31.4 K |
| ARVN | 306.7 K | 306.7 K | 306.7 K | 306.7 K | 306.7 K | 306.7 K | 306.7 K | 1 M | 2.8 M | 6.2 M | 6.4 M | 4.7 M | 6.8 M | 2.9 M | 4.3 M |
| ETNB | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 139 K | 126 K | 63 K | 7 K | 4 K | 3.8 K |
| MDGL | 769 K | 690 K | 505 K | 769 K | 144 K | 58 K | 3.1 K | 125 K | 22 K | 172 K | 334 K | 209 K | 217 K | 1.5 M | 1.6 M |
| ACLX | 479 K | 479 K | 479 K | 479 K | 479 K | 479 K | 479 K | 479 K | 479 K | 3.8 M | 888 K | 5.8 M | 2.3 M | 21.4 M | 22.5 M |
| DYN | 0.0 | 242 M | 0.0 | 98 M | 0.0 | 275 M | 326 M | 224 M | 134 K | 1.6 M | 1.2 M | 3.6 M | 3.1 M | 729 K | 692.5 K |
| CYTK | 6.6 M | 443 K | 125 K | 542 K | 1.1 M | 562 K | 1.6 M | 2.9 M | 889 K | 2.6 M | 11.1 M | 48.9 M | 11.3 M | 1.4 M | 1.3 M |
| RVMD | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.5 M | 2.6 M | 2.9 M | 6.5 M | 10.8 M | 7.7 M | 5.3 M |
| SNDX | 11 K | 11 K | 11 K | 38 K | 4 K | 49 K | 261 K | 84 K | 187 K | 129 K | 129 K | 129 K | 225 K | 0.0 | 0.0 |
| INZY | 259 K | 259 K | 259 K | 259 K | 259 K | 259 K | 259 K | 259 K | 259 K | 139 K | 568 K | 397 K | 410 K | 298 K | 379.7 K |
| PASG | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 1.7 M | 1.6 M | 25.6 M | 5.3 M | 146 K | 138.7 K |
Pliant Therapeutics and related stocks such as Relay Therapeutics, Stoke Therapeutics, and Black Diamond Therap Capital Expenditures description
Capital Expenditures are funds used by Pliant Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Pliant Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.My Equities
My Current Equities and Potential Positions
| Pliant Therapeutics | PLRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 13.56
Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.